Phase 2 N=116 Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Ovarian Neoplasm · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants
N/A N=124 Health Literacy in Patients With Congestive Heart Failure
Congestive Heart Failure
Primary: Re-hospitalization or Death — 48; 48 participants
Phase 3 N=835 Virtual Continuity and Its Impact on Complex Hospitalized Patients' Care
Automated Communication Tools · Complex Medical Patients
Primary: Medication Errors at Hospital Discharge — 645; 359 Errors
Phase 3 N=218 Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
Alzheimer Disease
Primary: Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral…
N/A N=2,393 An Electronic Alert System for In-Hospital Acute Kidney Injury
Acute Kidney Injury
Primary: Dialysis Within 7 Days — 87; 70 participants
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Phase 3 N=21,105 Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
Stroke · Atrial Fibrillation · Embolism
Primary: Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE). — 253; 182; 232 number of participants with event — p=<.0001
N/A N=15 Upper Airway Physical Therapy for the Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea Syndrome
Primary: Delta of Apnea Hypopnea Index (AHI) as Measured by Polysomnography (PSG) — 4.27 events per hour
N/A N=264 Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery
Peripheral Vascular Disease
Primary: Primary Safety Endpoint: Freedom From Death, Target Lesion Revascularization (TLR), or Any Amputation of the Index Limb to 30 (±7) Days. — 99.2; 99.6; 99.6; 100.0…
N/A N=62 Reproductive Hormonal Alterations in Obesity
Obesity
Primary: Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1) — 4.1; 3.6 IU/L
Phase 4 N=41 Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis
Interstitial Cystitis
Primary: Change in Pain Score (1-10, 10 is Most Pain) From Baseline, to Average Post op Pain Score in PACU — -1.46; -.025 units on a scale
N/A N=320 Group Physical Therapy for Knee Osteoarthritis
Osteoarthritis
Primary: Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) — 43.7; 43.7; 36.5; 39.1 units on a scale — p=0.1024
Phase 3 N=153 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 97.8; 95.2 percentage of participants
N/A N=300 Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary
Rhinitis
Primary: The Change From Baseline in the Mean of the 3 Single Symptom Scores (Blocked Nose, Sneezing and Running Nose) at the Closing/Final Visit. — -2 units on a scale